Funding Opportunity PAR-19-267 from the NIH Guide for Grants and Contracts. Funding Opportunity PurposeThe purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as pre-clinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses all objectives of the fiscal year (FY) 2019/2020 NIH strategic plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan), including research directed towards prevention and cure of HIV infection; next-generation therapies; understanding the roles of comorbidities, coinfections and complications; and cross-cutting activities such as research training and building capacity.

Funding Opportunity PAR-19-268 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct an annual intensive workshop/conference/meeting that addresses the needs of early stage HIV/AIDS researchers utilizing nonhuman primates (NHPs) as they translate preclinical research from NHPs to human clinical trials. The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/milestone-driven projects. Conference topics should also include other considerations such as statistical and host genetics considerations; methods to translate the results of NHP studies to clinical trials in humans; and how to develop new NHP research programs to better reflect clinical observations and findings in human HIV/AIDS patients.

Wellcome Sanger Institute: Job Reference 83461 Postdoctoral Fellow - Computational Salary range £31,897 - £39,240 (dependent on experience) plus excellent benefits Fixed Hinxton, Cambridgeshire, England

Funding Opportunity RFA-AI-19-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

Funding Opportunity RFA-AI-19-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

Notice NOT-HD-19-010 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-104 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-100 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-698 from the NIH Guide for Grants and Contracts

Notice NOT-RM-19-007 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Senior Software Developer - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Development-Operations Engineer - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Ensembl Compara Project Leader Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatics Developer Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: WormBase Project Leader Location: Cambridge, Cambridgeshire, England

Funding Opportunity PAR-19-265 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR)projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the design, implementation, and creation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

Funding Opportunity PAR-19-266 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the design, implementation, and creation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

Experience with reproductive biology, cellular and molecular biology or infectious disease would be beneficial, as would familiarity with bioinformatic analysis...
From University of Wisconsin–Madison - Thu, 02 May 2019 00:58:13 GMT - View all Madison, WI jobs

Salary £17,489 per annum plus benefits: Wellcome Sanger Institute: Job Reference 83463 Bioinformatics Apprentice - IT Salary £17,489 per annum plus benefits  4 year apprenticeship We are looking for enthusiastic Hinxton, Cambridgeshire, England

Funding Opportunity PAR-19-264 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other omic data integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving cancer research discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.